|ZS Pharma Inc -- USA Stock|| |
89.98 0.02 0.0222%
Senior Vice President General Counsel
Mr. Mark Asbury JD is Senior Vice President General Counsel of Zs Pharma Inc. He has served as Senior Vice President and General Counsel since July 2014. From June 2011 to June 2012 Mr. Asbury was the Vice President and General Counsel of Pharmacyclics a biopharmaceutical company. From October 1996 to June 2011 Mr. Asbury was at Genentech where he held a variety of positions most recently as Associate General Counsel and Senior Director of Transactional Law. From October 1992 to September 1996 Mr. Asbury worked for the law firm of Shearman Sterling where he specialized in corporate finance mergers and acquisitions and commercial debt financings
Age: 48 President Since 2014
Asbury earned his B.A. from Vanderbilt University and his JD from Stanford University.
The company has return on total asset (ROA)
of (0.99) %
which means that it has lost $0.99 on every $100 spent on asset. This is way below average.
The company currently holds 10.39 M in liabilities with Debt to Equity (D/E) ratio of 0.05 which may suggest the company is not taking enough advantage from borrowing. ZS Pharma Inc has Current Ratio of 10.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
ZS Pharma, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of nonabsorbed drugs to treat renal, cardiovascular, liver, and metabolic diseases. ZS Pharma Inc (ZSPH) is traded on NASDAQ General Markets in USA. It is located in TEXAS, U.S.A and employs 184 people. ZS Pharma is listed under Pharmaceutical Products category by Fama And French industry classification.